Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Etoposide and Quercetin

supplement:

Quercetin

Research Papers that Mention the Interaction

The present work is aimed to enhance the bioavailability of etoposide by co-administering it with quercetin (a P-gp inhibitor) in dual-loaded polymeric nanoparticle formulation.
Drug delivery  •  2016  |  View Paper
Quercetin significantly reduced the oxidative DNA damage caused by etoposide both in vitro and in vivo.
Acta biochimica Polonica  •  2014  |  View Paper
Evidence for the downstream TopoII‐independent mutagenic potential of Que was obtained by documenting further increased frequencies of MLL rearrangements in human HSPCs concomitantly treated with Etoposide and Que versus single treatments.
International journal of cancer  •  2017  |  View Paper
Quercetin significantly protected MPO-rich cells against the pro-oxidative (p<0.05) and apoptotic (p<0.05) effects of etoposide.
The protective action of quercetin against the pro-oxidant and apoptotic effect of etoposide was investigated in HL-60 cells with a high level of myeloperoxidase (MPO) activity and in cells treated with MPO inhibitor, 4-aminobenzoic acid hydrazide (ABAH).
Acta biochimica Polonica  •  2014  |  View Paper
Quercetin also inhibited DNA damage induced by etoposide and enhanced the inhibitory action of etoposide on the ROS formation in neutrophils.
We investigated whether quercetin , due to its antioxidant properties, is able to modulate the damaging activity of etoposide.
Toxicology in vitro : an international journal published in association with BIBRA  •  2007  |  View Paper
Consequently, compared to the control group (8.87%), the presence of quercetin significantly (5 mg/kg, p<0.05; 15 mg/kg, p<0.01) increased the absolute bioavailability (AB) of etoposide to 12.7 or 13.6% .
In the presence of quercetin , the pharmacokinetic parameters of etoposide were significantly altered in the oral group, but not in the i.v.
The dosage regimen of etoposide in cancer therapy should take drug interaction into consideration when etoposide is administered with quercetin or dietary supplements containing quercetin.
The presence of 5 or 15 mg/kg of quercetin significantly (p<0.05) decreased the total body clearance (CL/F) of oral etoposide.
The presence of quercetin significantly (5 mg/kg, p<0.05; 15 mg/kg, p<0.01) increased the area under the plasma concentration-time curve (AUC) of orally administered etoposide from 43.0 or 53.2% .
Anticancer research  •  2009  |  View Paper